CRISPR Therapeutics
CRSP
CRSP
424 hedge funds and large institutions have $3.52B invested in CRISPR Therapeutics in 2025 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 124 increasing their positions, 100 reducing their positions, and 58 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
424
Holders Change
+37
Holders Change %
+9.56%
% of All Funds
5.69%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
101
Increased
124
Reduced
100
Closed
58
Calls
$244M
Puts
$186M
Net Calls
+$58.2M
Net Calls Change
+$37.5M
Top Buyers
| 1 |
1
BlackRock
New York
|
$295M |
| 2 |
OAG
2
Orbis Allan Gray
Hamilton,
Bermuda
|
$134M |
| 3 |
3
Geode Capital Management
Boston,
Massachusetts
|
$101M |
| 4 |
4
State Street
Boston,
Massachusetts
|
$159M |
| 5 |
5
UBS Group
Zurich,
Switzerland
|
$138M |
Top Sellers
| 1 |
1
UBS AM
Chicago,
Illinois
|
$46.9M |
| 2 |
2
Morgan Stanley
New York
|
$24.9M |
| 3 |
3
Millennium Management
New York
|
$3.41M |
| 4 |
4
Capital International Investors
Los Angeles,
California
|
$272M |
| 5 |
BBA
5
Baker Bros. Advisors
New York
|
$0 |